(RTTNews) - Pharming Group N.V. (PHGUF.PK, PHGUF.OB, PHAR, PHARM.AS), a Netherlands-based biotechnology company focused on rare immune and genetic diseases, on Thursday reported increased preliminary revenue for the third quarter of fiscal 2026, driven by higher revenue from its
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.